Working… Menu

Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer (TARSEQ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01350817
Recruitment Status : Completed
First Posted : May 10, 2011
Last Update Posted : April 3, 2015
Hoffmann-La Roche
Information provided by (Responsible Party):
University Hospital, Limoges

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : March 2013
Actual Study Completion Date : January 2014